Update
$Nektar Therapeutics(NKTR.US$ Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255
MT Newswires· 1 min ago![]()
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and persistence of NK and CD8+ T cells to enhance specific anti-tumor activity," said the company. Nektar said the data was presented by its collaborators from the Cairo Laboratory at New York Medical College during a recent medical meeting.
NKTR-255, in combination with other cell therapies and immunotherapies, is currently under three clinical studies, Nektar said
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and persistence of NK and CD8+ T cells to enhance specific anti-tumor activity," said the company. Nektar said the data was presented by its collaborators from the Cairo Laboratory at New York Medical College during a recent medical meeting.
NKTR-255, in combination with other cell therapies and immunotherapies, is currently under three clinical studies, Nektar said
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
